ADVANTAGE MULTI 9 DIN 02263505
Health Canada record
| Active ingredient(s) | IMIDACLOPRID 40 MG; MOXIDECTIN 4 MG |
|---|---|
| Dosage form | Solution |
| Route | Topical |
| Schedule | PRESCRIPTION |
| Class | Veterinary |
| ATC | |
| Original market date | 01-Feb-2005 |
| Current status date | 28-Mar-2022 |
| Source | Health Canada DPD |
Establishment licence of the holder
Elanco Canada Limited — licence 102236, currently licensed, last inspection rating C (2022-08-03).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing IMIDACLOPRID
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02263556 | ADVANTAGE MULTI 10 | ELANCO CANADA LIMITED | Solution | IMIDACLOPRID 40 MG; MOXIDECTIN 10 MG | Marketed |
| 02263564 | ADVANTAGE MULTI 100 | ELANCO CANADA LIMITED | Solution | IMIDACLOPRID 400 MG; MOXIDECTIN 100 MG | Marketed |
| 02263513 | ADVANTAGE MULTI 18 | ELANCO CANADA LIMITED | Solution | IMIDACLOPRID 80 MG; MOXIDECTIN 8 MG | Marketed |
| 02263548 | ADVANTAGE MULTI 20 | ELANCO CANADA LIMITED | Solution | IMIDACLOPRID 100 MG; MOXIDECTIN 25 MG | Marketed |
| 02263521 | ADVANTAGE MULTI 55 | ELANCO CANADA LIMITED | Solution | IMIDACLOPRID 250 MG; MOXIDECTIN 62.5 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 24519 | 2020-10-28 | New Drug Submission (NDS) | CHANGE IN PRODUCCT OWNERSHIP |
| 17207 | 2015-08-19 | Supplement to a New Drug Submission (SNDS) | LABELLING UPDATE |
| 14982 | 2013-12-03 | Supplement to a New Drug Submission (SNDS) | ADDITIONAL INDICATION IN FELINE: INCLUSION OF FERRETS AS A NEW SPECIES AND INDICATIONS IN FERRETS |
| 7724 | 2006-01-31 | Supplement to a New Drug Submission (SNDS) | ADDITIONAL CLAIM |
| 6211 | 2005-01-17 | New Drug Submission (NDS) |
International API supply for IMIDACLOPRID
0 active FDA Drug Master Files.
Request a quote for ADVANTAGE MULTI 9